tbuckley/cabot-search huggingface dataset:
Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies
Authors: Martina Svenja Lutz, Boris Klimovich, Stefanie Maurer, Jonas S Heitmann, Melanie Märklin, Latifa Zekri, Gundram Jung, Helmut R Salih, Clemens Hinterleitner
Journal: Journal for ImmunoTherapy of Cancer (2022)

T cell-based immunotherapy, for example, with T cell-recruiting bispecific antibody (bsAb), has revolutionized oncological treatment. However, many patients do not respond to treatment, and long-term remissions are still rare. Several tumor immune evasion mechanisms have been reported to counteract efficiency of T cell-engaging therapeutics. Platelets largely affect cancer pathophysiology by mediating tumor invasion, metastasis, and immune evasion. On treatment of patients in a clinical trial with a PSMA×CD3 bsAb (NCT04104607), we observed profound treatment-associated platelet activation, mirrored by a decrease of total platelet count. On modeling the treatment setting, we found that platelet activation significantly reduced bsAb-mediated CD4+ and CD8+ T-cell reactivity as revealed by impaired T-cell degranulation, secretion of perforin, and ultimately, inhibition of target cell lysis. This effect occurred in a transforming growth factor beta (TGF-β)-dependent manner and was not restricted to PSMA×CD3 bsAb, but rather observed with various CD3-directed bispecific constructs, including the approved CD19×CD3 bsAb blinatumomab. BsAb-mediated T-cell reactivity could be restored by platelet inhibition and specifically by blocking the TGF-β axis. Together, our findings demonstrate that platelets undermine the efficacy of T cell-recruiting bsAb and identify modulation of platelet function as a means to reinforce the effectiveness of bsAb treatment.
Offline: COVID-19 and the dangers of Sinophobia
Authors: Richard Horton
Journal: The Lancet (2020)

One of the most productive experiences editors at The Lancet have had during the past 6 months has been the intense collaborations with medical and public health scientists in mainland China and Hong Kong. Cooperation began early in the pandemic. During the last week of January, The Lancet published five research papers from mainland China and Hong Kong describing the clinical presentation of patients with COVID-19, human-to-human transmission, genomic relatedness to the SARS coronavirus, and the risks of a global pandemic.
Clinical competence in electrocardiography
Authors: Charles Fisch, Thomas J. Ryan, Sankey V. Williams, James L. Achord, Masood Akhtar, Michael H. Crawford, Gottlieb C. Friesinger, Elmer J. Holzinger, Francis J. Klocke, Peter R. Kowey, Risa J. Lavizzo-Mourey, James Leonard, John B. O'connell, Robert A. O'rourke, William A. Reynolds, Patrick J. Scanlon, Robert C. Schlant, Donald E. Ware
Journal: Journal of the American College of Cardiology (1995)
Aprepitant for Cough in Lung Cancer. A Randomized Placebo-controlled Trial and Mechanistic Insights
Authors: Jaclyn A. Smith, Amélie Harle, Rachel Dockry, Kimberley Holt, Philip Russell, Alex Molassiotis, Janelle Yorke, Ryan Robinson, Mark A. Birrell, Maria G. Belvisi, Fiona Blackhall
Journal: American Journal of Respiratory and Critical Care Medicine (2020)

Effective cough treatments are a significant unmet need in patients with lung cancer. Aprepitant is a licensed treatment for nausea and vomiting, which blocks substance P activation of NK-1 (neurokinin 1) receptors, a mechanism also implicated in cough.
MAURICE C. PINCOFFS, EDITOR OF THE ANNALS
Authors: J. R. E.
Journal: Annals of Internal Medicine (1960)

Editorials1 October 1960MAURICE C. PINCOFFS, EDITOR OF THE ANNALSJ. R. E.J. R. E.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-53-4-847 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptFor the first time in twenty-seven years an issue of the Annals of Internal Medicine appears without the name of Maurice C. Pincoffs at the masthead. His period of editorship has been long and fruitful, so much so that the Annals and Dr. Pincoffs have come to have a single identity. For this long and honorable service the American College of Physicians and the readers of the Annals owe him an immeasurable debt of gratitude. To Maurice C. Pincoffs, retiring Editor, this issue of the Annals is dedicated.Elsewhere in this issue an account is given by a friend and... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byJ. Russell Elkinton, M.D., M.A.C.P.: A TributeMARSHALL N. FULTON, M.D. 1 October 1960Volume 53, Issue 4Page: 847-848KeywordsGratitude ePublished: 1 December 2008 Issue Published: 1 October 1960 PDF downloadLoading ...
Mentoring in the Era of #MeToo
Authors: Julie Story Byerley
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Metal-ion coordinated self-assembly of human insulin directs kinetics of insulin release as determined by preclinical SPECT/CT imaging
Authors: Gokce Engudar, Cristina Rodríguez-Rodríguez, Narendra Kumar Mishra, Marta Bergamo, Guillaume Amouroux, Knud J. Jensen, Katayoun Saatchi, Urs O. Häfeli
Journal: Journal of Controlled Release (2022)
Medical Greats
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
New Names for Salts
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Nasopharyngeal airway dual-transcriptome of infants with severe bronchiolitis and risk of childhood asthma
Authors: Zhaozhong Zhu, Carlos Camargo, Yoshihiko Raita, Robert Freishtat, Michimasa Fujiogi, Andrea Hahn, Jonathan Mansbach, Jonathan Spergel, Marcos Pérez-Losada, Kohei Hasegawa
Journal: Journal of Allergy and Clinical Immunology (2022)
A Hybrid Machine Learning Model Based on Semantic Information Can Optimize Treatment Decision for Naïve Single 3–5-cm HCC Patients
Authors: Wenzhen Ding, Zhen Wang, Fang-Yi Liu, Zhi-Gang Cheng, Xiaoling Yu, Zhiyu Han, Hui Zhong, Jie Yu, Ping Liang
Journal: Liver Cancer (2022)

Tumor recurrence is an abomination for hepatocellular carcinoma (HCC) patients receiving local treatment.The aim of the study was to build a hybrid machine learning model to recommend optimized first treatment (laparoscopic hepatectomy [LH] or microwave ablation [MWA]) for naïve single 3-5-cm HCC patients based on early recurrence (ER, ≤2 years) probability.This retrospective study collected 20 semantic variables of 582 patients (LH: 300, MWA: 282) from 13 hospitals with at least 24 months follow-up. Both groups were divided into training, validation, and test set, respectively. Five algorithms (logistics regression, random forest, neural network, stochastic gradient boosting, and eXtreme Gradient Boosting [XGB]) were used for model building. A model with highest area under the receiver operating characteristic curve (AUC) in a validation set of LH and MWA was selected to connect as a hybrid model which made decision based on ER probability. Model testing was performed in a comprehensive set comprising LH and MWA test sets.Four variables in each group were selected to build LH and MWA models, respectively. LH-XGB model (AUC = 0.744) and MWA-stochastic gradient method (AUC = 0.750) model were selected for model building. In the comprehensive set, a treatment confusion matrix was established based on recommended and actual treatment. The predicted ER probabilities were comparable with the actual ER rates for various types of patients in matrix (p > 0.05). ER rate of patients whose actual treatment consistent with recommendation was lower than that of inconsistent patients (LH: 21.2% vs. 46.2%, p = 0.042; MWA: 26.3% vs. 54.1%, p = 0.048). By recommending optimal treatment, the hybrid model can significantly reduce ER probability from 38.2% to 25.6% for overall patients (p < 0.001).The hybrid model can accurately predict ER probability of different treatments and thereby provide reliable evidence to make optimal treatment decision for patients with single 3-5-cm HCC.
Discordance Between Standard Equations for Determination of LDL Cholesterol in Patients With Atherosclerosis
Authors: Aparna Sajja, Hsin-Fang Li, Kateri J. Spinelli, Roger S. Blumenthal, Salim S. Virani, Seth S. Martin, Ty J. Gluckman
Journal: Journal of the American College of Cardiology (2022)
FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium
Authors: Quisette P Janssen, Jacob L van Dam, Deesje Doppenberg, Laura R Prakash, Casper H J van Eijck, William R Jarnagin, Eileen M O’ Reilly, Alessandro Paniccia, Marc G Besselink, Matthew H G Katz, Ching-Wei D Tzeng, Alice C Wei, Amer H Zureikat, Bas Groot Koerkamp
Journal: JNCI Journal of the National Cancer Institute (2022)

Abstract Background Large pragmatic studies of patients who received 5-fluorouracil with leucovorin, irinotecan, and oxaliplatin ([m]FOLFIRINOX) as initial treatment for localized pancreatic ductal adenocarcinoma (PDAC) are lacking. This study aimed to provide realistic estimates of oncologic outcomes in these patients. Methods This international retrospective cohort study included all consecutive patients presenting with localized PDAC who received at least 1 cycle of (m)FOLFIRINOX as initial treatment in 5 referral centers from the United States and the Netherlands (2012-2019). Primary outcome was median overall survival (OS), calculated from the date of tissue diagnosis, assessed using Kaplan-Meier estimates. Log-rank test was used to compare OS between groups. A Cox proportional hazards regression model was used to assess prognostic baseline factors for OS. All statistical tests were 2-sided. Results Overall, 1835 patients were included, of whom 958 (52.2%) had locally advanced (LA), 531 (28.9%) had borderline resectable (BR), and 346 (18.9%) had potentially resectable (PR) PDAC. The median number of (m)FOLFIRINOX cycles was 6 (interquartile range = 4-8). Subsequent treatment included second chemotherapy (12.9%), radiotherapy (49.0%), and resection (37.9%). The resection rate was 17.6% for LA, 53.1% for BR, and 70.5% for PR PDAC (P &amp;lt; .001). The margin-negative resection rate (&amp;gt;1 mm) was 55.2% for LA, 62.6% for BR, and 79.2% for PR PDAC (P &amp;lt; .001). The median OS was 18.7 months (95% confidence interval [CI] = 17.7 to 19.9 months) for LA, 23.2 months (95% CI = 21.0 to 25.7 months) for BR, and 31.2 months (95% CI = 26.2 to 36.6 months) for PR PDAC (P &amp;lt; .001). The median OS for 695 patients who underwent a resection was 38.3 months (95% CI = 36.1 to 42.0 months). Independent prognostic factors at baseline for worse OS were more advanced stage, worse performance status, baseline carbohydrate antigen (CA) 19-9 &amp;gt; 500 U/mL, and body mass index ≤18.5 kg/m2. Conclusions This large international cohort study provides realistic estimates of resection rates and survival in patients with LA, BR, and PR PDAC who started (m)FOLFIRINOX treatment in PDAC referral centers.
Cost-effectiveness and Economic Benefit of Continuous Professional Development for Drug Prescribing
Authors: David A. Cook, Christopher R. Stephenson, John M. Wilkinson, Stephen Maloney, Jonathan Foo
Journal: JAMA Network Open (2022)

<h3>Importance</h3> The economic impact of continuous professional development (CPD) education is incompletely understood. <h3>Objective</h3> To systematically identify and synthesize published research examining the costs associated with physician CPD for drug prescribing. <h3>Evidence Review</h3> MEDLINE, Embase, PsycInfo, and the Cochrane Database were searched from inception to April 23, 2020, for comparative studies that evaluated the cost of CPD focused on drug prescribing. Two reviewers independently screened all articles for inclusion and reviewed all included articles to extract data on participants, educational interventions, study designs, and outcomes (costs and effectiveness). Results were synthesized for educational costs, health care costs, and cost-effectiveness. <h3>Findings</h3> Of 3338 articles screened, 38 were included in this analysis. These studies included at least 15 659 health care professionals and 1 963 197 patients. Twelve studies reported on educational costs, ranging from $281 to $183 554 (median, $15 664). When economic outcomes were evaluated, 31 of 33 studies (94%) comparing CPD with no intervention found that CPD was associated with reduced health care costs (drug costs), ranging from $4731 to $6 912 000 (median, $79 373). Four studies found reduced drug costs for 1-on-1 outreach compared with other CPD approaches. Regarding cost-effectiveness, among 5 studies that compared CPD with no intervention, the incremental cost-effectiveness ratio for a 10% improvement in prescribing ranged from $15 390 to $437 027 to train all program participants. Four comparisons of alternative CPD approaches found that 1-on-1 educational outreach was more effective but more expensive than group education or mailed materials (incremental cost-effectiveness ratio, $18-$4105 per physician trained). <h3>Conclusions and Relevance</h3> In this systematic review, CPD for drug prescribing was associated with reduced health care (drug) costs. The educational costs and cost-effectiveness of CPD varied widely. Several CPD instructional approaches (including educational outreach) were more effective but more costly than comparators.
Lessons learned from proton vs photon radiation therapy for glioblastoma signal-finding trial
Authors: Caroline Chung, Paul D Brown, Jeffrey S Wefel
Journal: Neuro-Oncology (2022)

We appreciate the astute comments of Drs Vogelius and Bentzen regarding the analyses reported in association with our phase II randomized trial of proton therapy (PT) vs intensity-modulated radiotherapy (IMRT) for patients with newly diagnosed glioblastoma (GBM).1 To address their question about the differences in the reported numbers, the abstract in 2017 reported the intention-to-treat (ITT) analysis of the available patients with completed follow-up whereas the final report presented updated ITT analyses as well as the important per-protocol analysis. The per-protocol analysis included a shift of 2 patients who were assigned to protons but received IMRT due to insurance denial for protons. This raises the learned challenges that were faced within this randomized trial comparing two radiation modalities that relied on insurance approvals even within the clinical trial context. We do summarize that although 90 patients consented, the analysis consisted of 67 patients because “the majority of patients were excluded before treatment began due to insurance denial of proton therapy” (p. 1340). There was a further loss of evaluable patients due to loss of follow-up, limiting the evaluable patients who completed neurocognitive function testing, our primary study endpoint. It is possible that further bias may have been introduced in the patients who chose to remain on study vs those who chose to no longer participate or were lost to follow-up. Due to these various competing factors that limited the evaluable patients as well as the primary goal of evaluating the cognitive effects of two treatments, we reported the per-protocol analysis in order to try and associate cognitive toxicity of the treatment received and its related brain dosimetry. When seeking to understand the differences particularly in treatment-related toxicity between treatments in small phase II signal-finding trials, we argue that there is substantial value to ensuring you are comparing the clinical outcomes relative to delivered treatments, which requires an effective treatment analysis approach. Given the various lessons learned and challenges faced, we congratulate the forethought of the ongoing randomized proton trials that integrated more sophisticated randomization and trial designs to help address some of these challenges.
Clinical Characteristics may help predict refractoriness to endoscopic sinus surgery in patients with Chronic Rhinosinusitis
Authors: Meera Ganesh, Alexander Schneider, Caroline Price, Liqi Chen, Samuel Rodeghiero, Samuel Racette, Abhita Reddy, Julia Huang, David Lehmann, Jacob Eide, Joan Chmiel, David Conley, Kevin Welch, Robert Kern, Stephanie Shintani Smith, Anju Peters, Atsushi Kato, Whitney Stevens, Robert Schleimer, Bruce Tan
Journal: Journal of Allergy and Clinical Immunology (2022)
Myocardial imaging.
Journal: BMJ (1978)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Myocardial imaging. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Patients' Education and Doctors' “Report Cards”
Journal: Annals of Internal Medicine (1999)

Summaries for Patients16 November 1999Patients' Education and Doctors' “Report Cards”Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-131-10-199911160-00043 SectionsAboutFull Text ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Over recent years, managed care organizations and others have begun to develop “report cards” to measure the quality of doctors' practices. How well a physician does on these report cards has a lot to do with how sick the doctor's patients are. For example, a doctor who cares for many cancer patients will undoubtedly have a higher patient death rate than will a doctor who cares for mainly young, healthy people. It is very important that these “report cards” account for the levels of sickness of the patients ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Influence of Patient Education on Profiles of Physician Practices.” It is in the 16 November 1999 issue of Annals of Internal Medicine (volume 131, pages 745-751). The authors are K. Fiscella and P. Franks.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoInfluence of Patient Education on Profiles of Physician Practices Kevin Fiscella and Peter Franks Metrics 16 November 1999Volume 131, Issue 10Page: 745KeywordsCholesterolDeath ratesMedical services ePublished: 15 August 2000 Issue Published: 16 November 1999 Copyright & PermissionsCopyright © 1999 by American College of Physicians. All Rights Reserved.Loading ...